6/28/23, 12:14 AM COLCOT Pathway Feedback Search Clinical Topics Home Studies COLCOT COLCOT Disease Disease Non-ST-elevation myocardial inf ST-elevation myocardial infarction Trial question What is the effect of low-dose colchicine in patients after a myocardial infarction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 19.0% female N = 4745 81.0% male 4745 patients (909 female, 3836 male) Inclusion criteria: adult patients who had a myocardial infarction within 30 days of enrollment Key exclusion criteria: severe HF, stroke within the previous 3 months, IBD or chronic diarrhea, neuromuscular disease, severe renal disease, severe hepatic disease, a history of clinically significant sensitivity to colchicine Interventions N=2366 colchicine (at a dose of 0.5 mg once daily) N=2379 placebo (matching 0.5 mg sugar pill once daily) Primary outcome Death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization 7.1 7.1 % 5 5 https://web.pathway.md/studies/rec5ikA6cDV6BUP4j 1/2 6/28/23, 12:14 AM COLCOT Pathway 5.5 5.3 % 3.5 % Significant decrease NNT = 63 1.8 % 0.0 % Colchicine Placebo Significant decrease in death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization (5.5% vs. 7.1%; HR 0.77, 95% CI 0.61 to 0.96) Secondary outcomes No significant difference in death from cardiovascular causes, cardiac arrest, myocardial infarction, or stroke (4.7% vs. 5.5%; HR 0.85, 95% CI 0.66 to 1.1) No significant difference in deep vein thrombosis or PE (0.4% vs. 0.3%; HR 1.43, 95% CI 0.54 to 3.75) Safety outcomes No significant differences in adverse events, serious adverse events, diarrhea. Significant differences in pneumonia (0.9% vs. 0.4%), nausea (1.8% vs. 1.0%). Conclusion In adult patients who had a myocardial infarction within 30 days of enrollment, colchicine was superior to placebo with respect to death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. Reference Jean-Claude Tardif, Simon Kouz, David D Waters et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. Open reference URL https://web.pathway.md/studies/rec5ikA6cDV6BUP4j 2/2